XY Capital Ltd Acquires 5,970 Shares of Novartis AG $NVS

XY Capital Ltd raised its holdings in shares of Novartis AG (NYSE:NVS) by 213.2% in the first quarter, Holdings Channel reports. The institutional investor owned 8,770 shares of the company’s stock after buying an additional 5,970 shares during the quarter. Novartis accounts for about 1.3% of XY Capital Ltd’s portfolio, making the stock its 25th biggest holding. XY Capital Ltd’s holdings in Novartis were worth $1,340,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. PNC Financial Services Group Inc. grew its stake in shares of Novartis by 4.7% in the first quarter. PNC Financial Services Group Inc. now owns 220,134 shares of the company’s stock worth $33,625,000 after acquiring an additional 9,930 shares during the last quarter. Glenview Trust Co raised its stake in Novartis by 4.8% during the 1st quarter. Glenview Trust Co now owns 1,629 shares of the company’s stock valued at $249,000 after purchasing an additional 75 shares during the last quarter. Cassaday & Co Wealth Management LLC bought a new stake in Novartis in the 1st quarter valued at $62,000. Leith Wheeler Investment Counsel Ltd. bought a new stake in Novartis in the 1st quarter valued at $221,000. Finally, Earned Wealth Advisors LLC grew its position in Novartis by 15.8% in the 1st quarter. Earned Wealth Advisors LLC now owns 2,284 shares of the company’s stock worth $349,000 after purchasing an additional 311 shares during the last quarter. 13.12% of the stock is owned by institutional investors.

Key Stories Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis topped Q2 earnings estimates, posting $2.41 per share versus $2.17 expected, while revenue also came in above forecasts. The beat was driven by strong demand for key drugs and lower-than-expected costs. Novartis earnings report
• Positive Sentiment: The company returned to sales growth in Q2 as newer medicines offset generic pressure, with strength in cancer and multiple sclerosis treatments helping support results. Reuters Q2 profit story
• Positive Sentiment: Management reaffirmed full-year 2026 guidance, which suggests confidence that growth from newer products can continue despite headwinds. Zacks earnings recap
• Neutral Sentiment: Investors are also watching upcoming late-stage trial readouts in the second half of the year, which could influence the stock’s longer-term valuation narrative. Reuters pipeline valuation story
• Negative Sentiment: Ongoing generic competition and a sharp drop in Entresto sales remain major headwinds, and investors may worry about pressure on older blockbusters. Invezz Entresto sales drop story

Novartis Trading Up 2.8%

Shares of NVS opened at $153.82 on Wednesday. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96. The stock has a market cap of $293.51 billion, a PE ratio of 22.04, a PEG ratio of 2.58 and a beta of 0.45. Novartis AG has a 1 year low of $112.34 and a 1 year high of $170.46. The stock has a 50 day simple moving average of $151.61 and a 200-day simple moving average of $151.88.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a return on equity of 38.82% and a net margin of 24.87%.The business had revenue of $14.95 billion for the quarter. On average, sell-side analysts predict that Novartis AG will post 8.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NVS has been the topic of a number of recent research reports. Morgan Stanley lifted their target price on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research report on Thursday, March 26th. Weiss Ratings downgraded Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $141.20.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.